Symbol="LYEL"
AssetType="Common Stock"
Name="Lyell Immunopharma Inc"
Description="Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington."
CIK="1806952"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="771292000"
EBITDA="-162159008"
PERatio="None"
PEGRatio="None"
BookValue="3.14"
DividendPerShare="0"
DividendYield="0"
EPS="-0.7"
RevenuePerShareTTM="0.339"
ProfitMargin="-2.161"
OperatingMarginTTM="-2.15"
ReturnOnAssetsTTM="-0.116"
ReturnOnEquityTTM="-0.218"
RevenueTTM="84195000"
GrossProfitTTM="84683000"
DilutedEPSTTM="-0.7"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.882"
AnalystTargetPrice="7.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.91"
PriceToBookRatio="1.066"
EVToRevenue="7.42"
EVToEBITDA="-1.436"
Beta="-1.427"
num_52WeekHigh="8.74"
num_52WeekLow="1.77"
num_50DayMovingAverage="2.997"
num_200DayMovingAverage="3.516"
SharesOutstanding="249609000"
DividendDate="None"
ExDividendDate="None"
symbol="LYEL"
open="3.01"
high="3.20"
low="3.01"
price="3.09"
volume="951124.00"
latest_trading_day="2023-07-18"
previous_close="3.00"
change="0.09"
change_percent="3.0000%"
aroon_positive_momentum_days="44"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="1120138"
Change_recent_avg="0.01"
Delta_recent_avg="0.24"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.02"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="1114"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0147.jpeg"
image_negative_thumbnail_id_2="490"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_neutral_thumbnail_id_1="598"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_neutral_thumbnail_id_2="562"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0037.jpeg"
image_positive_thumbnail_id_1="682"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0026.jpeg"
image_positive_thumbnail_id_2="990"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0152.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
